Overcoming Obstacles: RSV Treatment for Infants in Oregon

Two new therapies, nirsevimab (Beyfortus) and the Pfizer RSV vaccine, have the potential to significantly reduce the risk of lung infections in infants caused by respiratory syncytial virus (RSV). However, the rollout of these therapies in Oregon faces obstacles. The high cost of Beyfortus, at $495 per dose, combined with the strict rules governing the distribution of free shots to Medicaid-covered children, has made the rollout challenging. Additionally, concerns about potential preterm births associated with the maternal RSV vaccine may limit its uptake. Experts are worried that not all babies will have equal access to these therapies, potentially leaving some at risk for severe RSV complications.